Peptides Inhibit TLR Signaling for Hearing Loss
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for noise-induced and age-related hearing loss are inadequate in effectively addressing inflammation and improving hearing thresholds, as they fail to target the underlying inflammatory responses triggered by pathogens and tissue damage.
Innovation Solution
Administration of specific peptides, such as P13, derived from A52R or A52R-like proteins, which inhibit Toll-like receptor (TLR) signaling, thereby reducing inflammation and improving hearing by modulating cytokine secretion and cellular activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for noise-induced and age-related hearing loss are used, then hearing thresholds are maintained at current levels, but inflammation is not effectively reduced and hearing improvement is insufficient
Solution Approach 1:
The patent uses peptides (such as P13) as intermediary substances that specifically bind to and inhibit Toll-like receptors (TLRs). These peptides act as mediators between the inflammatory response and the treatment, blocking the harmful signaling cascade initiated by PAMPs while preventing excessive inflammation. The peptides serve as a bridge that modulates the immune response without completely suppressing it, thereby reducing inflammation effectively while maintaining hearing function.
2Object-affected harmful factors
If TLR signaling is inhibited to reduce inflammation, then cytokine secretion is reduced and inflammation decreases, but the ability to respond to pathogens may be compromised
Solution Approach 1:
The patent employs peptides that provide partial inhibition of TLR signaling rather than complete blockade. The peptides partially suppress the inflammatory response by modulating cytokine secretion, reducing excessive inflammation while preserving sufficient immune response capability. This partial action allows the system to maintain pathogen recognition and response abilities while preventing harmful levels of inflammation, achieving a balanced therapeutic effect.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptides significantly reduce middle ear inflammation, fluid accumulation, and hearing loss by inhibiting TNF-α secretion and enhancing hearing thresholds in animal models, demonstrating potential for treating noise-induced and age-related hearing loss.
Implementation Method 1
Toll-like receptors (TLRs) recognize and respond to conserved motifs termed 'pathogen-associated molecular patterns' (PAMPs). TLRs are characterized by an extracellular leucine-rich repeat motif and an intracellular Toll/IL-1 receptor (TIR) domain. Triggering of TLRs by PAMPs initiates a series of intracellular signaling events resulting in an inflammatory immune response
Data Source
AI summary
Peptides for the treatment of inflammation, and therapeutic uses and methods of using the same are disclosed. Peptides including a transducing sequence are effective for inhibiting cytokine activity and TNF-α secretion through interaction with toll-like receptor signaling pathways. Experiments are described illustrating the efficacy of the compounds in treating otitis media, noise-induced hearing loss, age-related hearing loss, and improvement of ordinary hearing.